Key result
Lower MCP-1 levels are linked to ~2.5-fold higher odds of left ventricular hypertrophy.
Why the study?
Are MCP-1 levels associated with resistant hypertension or left ventricular hypertrophy in hypertensive patients?
Cross-Sectional (n=256)
Single-blind
No
Are MCP-1 levels associated with resistant hypertension or left ventricular hypertrophy in hypertensive patients?
MCP-1 levels are downregulated in hypertensive patients with left ventricular hypertrophy, but do not differ between resistant and mild-to-moderate hypertension.
Answers are grounded in this paper and cite their sources.
MCP-1 measurement should not guide hypertension care; leaves open its LVH biomarker role and requires prospective validation.
Background: Hypertension is a chronic, low-grade inflammation process associated with the release of cytokines and development of target organ damage. Deregulated monocyte chemoattractant protein-1 (MCP-1) levels have been associated with high blood pressure and cardiovascular complications; however, the mechanisms involved are complex and not fully understood. Objective: This study aimed to compare the levels of MCP-1 in patients with resistant (RH) versus mild-to-moderate (HTN) hypertension and their association with the presence or absence of left ventricular hypertrophy (LVH) in all hypertensive subjects. Methods: We enrolled 256 hypertensive subjects: 120 RH and 136 HTN, investigating the relationship between circulating MCP-1 levels and blood pressure, biochemical data, hematologic profile, and cardiac damage within the RH and HTN groups. Plasma MCP-1 levels were measured by ELISA and LVH was assessed by echocardiography. Results: We found no difference in MCP-1 levels between RH and HTN subjects. On the other hand, we encountered lower MCP-1 levels in patients with LVH (105 pg/mL [100 - 260 pg/mL] versus 136 pg/mL (100 - 200 pg/mL), p = 0.005, respectively] compared with those without LVH. A logistic regression model adjusted for body mass index (BMI), age, race, aldosterone levels, and presence of diabetes and RH demonstrated that median levels of MCP-1 (2.55 pg/mL [1.22 - 5.2 pg/mL], p = 0.01) were independently associated with LVH in the entire hypertensive population. Conclusion: Since MCP-1 levels were similar in both RH and HTN subjects and decreased in hypertensive patients with existing LVH, our study suggests a possible downregulation in MCP-1 levels in hypertensive individuals with LVH, regardless of hypertension strata.
No takes yet. Share an insight, caveat, or question.
Ritter et al. (2017) conducted a cross-sectional in Hypertension (resistant hypertension and mild-to-moderate hypertension) (n=256). Low plasma MCP-1 levels (< 125 pg/mL) vs. Higher plasma MCP-1 levels (≥ 125 pg/mL) / Mild-to-moderate hypertension was evaluated on Presence of left ventricular hypertrophy (LVH) (OR 2.55, 95% CI 1.22-5.2, p=0.01). Lower plasma MCP-1 levels were independently associated with left ventricular hypertrophy, with no difference between resistant and mild hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: